Literature DB >> 9569190

A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen.

T K Giri1, A Hillarp, Y Härdig, B Zöller, B Dahlbäck.   

Abstract

A new method to determine the concentration of free protein S in plasma is described. It is an enzyme-linked ligandsorbent assay (ELSA) which utilises the protein S binding capacity of the natural ligand C4b-binding protein (C4BP) to capture the free protein S from plasma samples. The use of C4BP as ligand in the assay is possible due to the high affinity (Kd = 0.1 nM) of the interaction between protein S and C4BP and to a slow rate of complex dissociation. A monoclonal antibody (HPS 54) was conjugated with horseradish peroxidase and used as target antibody. This antibody recognises a Ca2+ dependent epitope in the first EGF-like domain of protein S and does not interfere with C4BP binding sites of protein S. Addition of calcium in the assay helped prevent dissociation of the C4BP-protein S-HPS 54 complex. Three different experiments demonstrated the assay to be specific for free protein S. First, near-identical dose response curves were obtained with protein S in plasma and with purified protein S. Second, addition of purified C4BP to normal plasma resulted in loss of free protein S. Third, protein S depleted plasma gave zero values and around 80% of purified protein S added to protein S depleted plasma, and approximately 70% of protein S added to protein S deficient plasma samples, was recovered with the assay. The assay is fast (involves only a single incubation step of 30 min), sensitive and the range of measurement is 3% to 200% of free protein S when plasma dilution 1:20 represents 100%. Intra- and inter-assay coefficients of variation at two levels were 2.3-4.3% and 5.1-7.4%, respectively. In a large protein S deficient family, the assay showed 100% sensitivity and specificity for the causative mutation. Moreover, free protein S levels in anticoagulated protein S deficient patients were completely separated from those obtained in non-anticoagulated controls. The new assay for free protein S is suitable for automation and it provides a useful means for routine clinical purposes to detect protein S deficiencies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569190

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients.

Authors:  Abrar Ahmad; Ashfaque A Memon; Jan Sundquist; Peter J Svensson; Bengt Zöller; Kristina Sundquist
Journal:  Gene       Date:  2018-01-09       Impact factor: 3.688

2.  Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner.

Authors:  Kristina Sundquist; Abrar Ahmad; Peter J Svensson; Bengt Zöller; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

3.  Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism.

Authors:  Abrar Ahmad; Kristina Sundquist; Bengt Zöller; Peter J Svensson; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

4.  Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism.

Authors:  Abrar Ahmad; Kristina Sundquist; Bengt Zöller; Peter J Svensson; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

5.  Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP.

Authors:  Adrienn Teraz-Orosz; Magdalena Gierula; Anastasis Petri; David Jones; Renos Keniyopoullos; Patricia Badia Folgado; Salvatore Santamaria; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  Blood Adv       Date:  2022-01-25

6.  Risk prediction of recurrent venous thromboembolism: a multiple genetic risk model.

Authors:  Abrar Ahmad; Kristina Sundquist; Karolina Palmér; Peter J Svensson; Jan Sundquist; Ashfaque A Memon
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.